Notice NOT-AT-22-002 from the NIH Guide for Grants and Contracts

Notice NOT-HD-21-051 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-AI-22-004 from the NIH Guide for Grants and Contracts

Notice NOT-DC-22-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-071 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Funding Opportunity PAR-22-072 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the measurement and assessment of complex constructs relevant to minority health and health disparities.

Notice NOT-NR-22-006 from the NIH Guide for Grants and Contracts

Notice NOT-NR-22-005 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-004 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-040 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-047 from the NIH Guide for Grants and Contracts

Notice NOT-DE-21-015 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-055 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-073 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Funding Opportunity Announcement (FOA), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.

Funding Opportunity PAR-22-067 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-028 This Funding Opportunity Announcement (FOA) solicits research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories in rodents or non-human primates and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R21 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R01 grant applications.

Funding Opportunity RFA-NS-22-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The CCC will facilitate implementation of clinical trials and will promote high quality and efficient timeliness in trial execution through such methods as master trial agreements and a central Institutional Review Board. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Funding Opportunity RFA-NS-22-013 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) for Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The DCC will have responsibility for data management, data quality, statistical analysis, Data Safety Monitoring Board(s) (DSMB) and reporting to regulatory and oversight groups. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Funding Opportunity RFA-NS-22-015 from the NIH Guide for Grants and Contracts. (Reissue of RFA-NS-16-016) The purpose of this funding opportunity announcement (FOA) is to invite applications from new and existing sites to serve as Clinical Centers (Hubs) in the SIREN Network. SIREN conduct of several multi-center Phase III clinical trials, to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and traumatic conditions. SIREN is made up of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and 11 clinical centers (Hubs). A Hub is usually an academic center or tertiary referral center which actively enrolls patients into all of the clinical trial performed in SIREN. Hubs also provide scientific leadership and administrative oversight to their multiple satellite sites ("Spokes"). Together the Hub and Spokes provide access to a large and varying patient population for clinical trials. SIREN performs a number of simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials are meritorious, peerreviewed projects which are awarded under separate funding announcements.